Characteristic | All patients (n=205) |
Sex, n (%) | |
Female | 82 (40.0) |
Male | 123 (60.0) |
Median (range) age, years | 35.0 (18.0–79.0) |
Race, n (%) | |
White | 166 (81.0) |
Asian | 28 (13.7) |
Multiracial* | 6 (2.9) |
Black or African American | 5 (2.4) |
Median (range) disease duration, y ears | 3.9 (0.3–38.8) |
Disease extent | |
Left-sided colitis | 97 (47.3) |
Pancolitis (extensive) | 64 (31.2) |
Unknown | 44 (21.5) |
Mean (SD) partial Mayo score | 6.4 (1.40) |
Mean (SD) full Mayo score (n=92) | 8.7 (1.65) |
Stool frequency score (SFS), n (%) | |
SFS 0 (Normal) | 3 (1.5) |
SFS 1 (1–2 stools more than normal) | 16 (7.8) |
SFS 2 (3–4 stools more than normal) | 64 (31.2) |
SFS 3 (≥5 stools more than normal) | 122 (59.5) |
Rectal bleeding score (RBS), n (%) | |
RBS 0 (No blood seen)† | 6 (2.9) |
RBS 1 (Streaks of blood with stool less than half of the time) | 77 (37.6) |
RBS 2 (Obvious blood with stool most of the time) | 94 (45.9) |
RBS 3 (Blood alone passed) | 28 (13.7) |
Endoscopic findings (n=92), n (%) | |
Mild disease‡ | 5 (5.4) |
Moderate disease§ | 58 (63.0) |
Severe disease¶ | 29 (31.5) |
Physician global assessment (PGA), n (%) | |
PGA 0 (Normal) | 1 (0.5) |
PGA 1 (Mild disease) | 1 (0.5) |
PGA 2 (Moderate disease) | 150 (73.2) |
PGA 3 (Severe disease) | 53 (25.9) |
Concomitant medications, n (%) | |
5-Aminosalicylates | 145 (70.7) |
Azathioprine | 93 (45.4) |
Corticosteroids | 80 (39.0) |
6-Mercaptopurine | 19 (9.3) |
Methotrexate | 6 (2.9) |
*Defined as have ≥2 of American Indian or Alaska native, black or African-American, Native Hawaiian or other Pacific islander, White or Asian.
†The six patients with rectal bleeding subscore 0 were included in the analysis; no patient selection was performed for the analysis.
‡Mild disease = erythema , decreased vascular pattern, mild friability.
§Moderate disease = marked erythema , absent vascular pattern, friability, erosions.
¶Severe disease = spontaneous bleeding , ulceration.